Gilead, the manufacturer of two of the biggest-selling HIV drugs in the world, tenofovir and emtricitabine, has announced that it has begun human studies of a product that could replace ritonavir as an antiretroviral boosting agent in some... more>

Monkeys infected with schistosomes (parasitic worms common in Africa) were substantially more susceptible to infection with a simian equivalent of HIV than those without the worm, researchers have found. They say their findings suggest... more>

Burkinabe women with HIV-1 and HSV-2 coinfections had significantly elevated genital and plasma HIV-1 viral loads due to HSV-2 reactivations, according to the findings of a randomised placebo-controlled trial published in the 15th... more>

today's news

• Gilead now testing ritonavir replacement in human studies
• Parasitic worm increases HIV infection risk
• Herpes simplex virus type 2 reactivations contribute to genital and plasma HIV-1 shedding
• Low level of drug-resistant strains common in untreated patients, but may not affect treatment
• HIV persists in the breastmilk of HIV-positive Kenyan mothers on antiretroviral treatment